000 | 01903 a2200565 4500 | ||
---|---|---|---|
005 | 20250515230346.0 | ||
264 | 0 | _c20111220 | |
008 | 201112s 0 0 eng d | ||
022 | _a1365-2893 | ||
024 | 7 |
_a10.1111/j.1365-2893.2010.01340.x _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aHofer, H | |
245 | 0 | 0 |
_aPrevalence and clinical significance of GB virus type C/hepatitis G virus coinfection in patients with chronic hepatitis C undergoing antiviral therapy. _h[electronic resource] |
260 |
_bJournal of viral hepatitis _cJul 2011 |
||
300 |
_a513-7 p. _bdigital |
||
500 | _aPublication Type: Journal Article | ||
650 | 0 | 4 | _aAdolescent |
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAged |
650 | 0 | 4 |
_aAntiviral Agents _xtherapeutic use |
650 | 0 | 4 |
_aCoinfection _xdiagnosis |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 |
_aFlaviviridae Infections _xdiagnosis |
650 | 0 | 4 | _aGB virus C |
650 | 0 | 4 |
_aHepatitis C, Chronic _xdiagnosis |
650 | 0 | 4 |
_aHepatitis, Viral, Human _xdiagnosis |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aInterferon-alpha _xtherapeutic use |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 |
_aPolyethylene Glycols _xtherapeutic use |
650 | 0 | 4 | _aPolymerase Chain Reaction |
650 | 0 | 4 | _aPrevalence |
650 | 0 | 4 |
_aRNA, Viral _xisolation & purification |
650 | 0 | 4 |
_aRecombinant Proteins _xtherapeutic use |
650 | 0 | 4 |
_aRibavirin _xtherapeutic use |
650 | 0 | 4 | _aRisk Factors |
650 | 0 | 4 |
_aSubstance Abuse, Intravenous _xvirology |
650 | 0 | 4 | _aTreatment Outcome |
700 | 1 | _aAydin, I | |
700 | 1 | _aNeumueller-Guber, S | |
700 | 1 | _aMueller, C | |
700 | 1 | _aScherzer, T-M | |
700 | 1 | _aStaufer, K | |
700 | 1 | _aSteindl-Munda, P | |
700 | 1 | _aWrba, F | |
700 | 1 | _aFerenci, P | |
773 | 0 |
_tJournal of viral hepatitis _gvol. 18 _gno. 7 _gp. 513-7 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-2893.2010.01340.x _zAvailable from publisher's website |
999 |
_c19914194 _d19914194 |